

学会発表(国内学会)

2023.07 第 30 回日本遺伝子診療学会大会、第 8 回クリニカルバイオバンク学会シンポジウム合同学術集会

1. がん遺伝子パネル検査の解析成功率の向上を目的とした後方視的解析.

井本 清美, 大池 信之, 小池 淳樹, 柳澤 信之, 野呂瀬 朋子, 大川 千絵, 島田 直樹, 新井 裕之, 武田 弘幸, 山本博幸, 若松 宏武, 佐藤 知雄, 砂川 優, 山野 嘉久.

2023.09 第 59 回日本胆道学会学術集会

1. 切除不能または再発胆道癌患者に対する二次以降の薬物療法としての FOLFOX 療法の有効性及び安全性の検討 (JON-2107B).

千田彰彦、寺島健志、森實千種、戸高 明子、梅本 久美子、川上裕次郎、上野誠、古瀬純司、永野浩和.

2023.10 第 61 回日本癌治療学会学術集会

1. がん診療におけるリアルワールドデータ(RWD)収集に関する多施設共同研究.

松本繁巳, 武藤学, 福山啓太, 山本秀和, 室圭, 砂川優, 安井久晃, 大槻涼, 木村裕一, 岡田昌史, 西浦亮二, 湯川洋一郎.

2. Cyber Oncology[®] を活用した進行胃癌治療の real-world data 構築のための実行可能性研究.

松本繁巳, 門脇重憲, 町田望, 仁科智裕, 砂川 優, 前北隆雄, 西岡真理子, 後藤知之, 浜本康夫, 安井久晃, 川邊里紗, 岡田昌史, 武藤学, 室圭.

3. 免疫チェックポイント阻害薬による間質性肺炎に対する治療実態調査.

野崎智椰, 横溝綾子, 伊澤直樹, 森川慶, 武田弘幸, 新井裕之, 土井綾子, 堀江良樹, 久保田洋平, 幕内麻里, 森田一, 砂川優, 坂上逸孝.

4. DEEPER 試験(mFOLFOXIRI+Cet vs Bev)の BRAF 追加解析報告.

間中大, 塩澤学, 河合毅, 太田博文, 安井久晃, 薮野太一, 鄭充善, 東風貢, 松橋延壽, 竹内正弘, 市川度, 藤井雅志, 砂川優, 辻晃仁.

2023.11 第 78 回日本大腸肛門病学会

1. 切除不能進行再発大腸癌におけるがん遺伝子パネル検査の臨床実装.

砂川優.

2023.12 第 36 回日本バイオセラピー学会学術集会総会

1. 免疫チェックポイント阻害薬の効果は予測できるか？

砂川優.

1. Clinical course of skin rashes caused by neoadjuvant gemcitabine plus S-1 for resectable pancreatic cancer.
横溝綾子, 梅本久美子, 秋野幸, 森田一, 湊川紘子, 前田幹広, 久保田洋平, 武田弘幸, 土井綾子, 堀江良樹, 新井裕之, 伊澤直樹, 砂川優, 坂上逸孝.
2. Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology®: A feasibility study.
町田望, 門脇重憲, 仁科智裕, 砂川優, 前北隆雄, 松本繁巳, 西岡真理子, 後藤知之, 浜本康夫, 安井久晃, 古田光寛, 梶原猛史, 新井裕之, 北野雅之, 長島文夫, 川邊里紗, 岡田昌史, 武藤学, 室圭.
3. A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy.
土井綾子, 加賀保行, 久保田洋平, 武田弘幸, 梅本久美子, 新井裕之, 堀江良樹, 小倉孝氏, 伊澤直樹, 堀部恵梨佳, 丹澤和雅, 砂川優.
4. ゲノムガイドシステムを用いた包括的がんゲノムプロファイリングの実装データの構築.
砂川優, 新井裕之, 山本博幸, 本吉愛, 右田王介, 大原樹, 古屋直樹, 井本清美, Stephan Het-tich, Ibrahim Avi Cemel, Lenka Kyjacova, Marc-Alexander Rauschendorf.
5. Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13).
夏目壮一郎, 関川高志, 高金明典, 澤田憲太郎, 伴登宏行, 山田知弘, 中山裕史, 内間恭武, 白石 猛, 木崎潤也, 古谷卓三, 竹内正弘, 市川度, 藤井雅志, 砂川優, 辻晃仁.
6. Anti-EGFR therapy for RAS mutant mCRC without RAS mutations in ctDNA after 1st or 2nd-line chemotherapy: JACCRO CC-17.
小野由香利, 伊澤直樹, 松原裕樹, 仁科慎一, 傳田忠道, 太田博文, 徳永卓哉, 陳凌風, 進藤吉明, 下川穂積, 藤田秀人, 岡本健, 石黒智之, 坂本康寛, 賀川義規, 佐竹悠良, 竹内正弘, 市川度, 藤井雅志, 砂川優.
7. 患者と主治医の抗がん剤による副作用のつらさと休薬希望度の差に関する意識調査.
小島拓, 伊澤直樹, 小倉孝氏, 土井綾子, 堀江良樹, 新井裕之, 武田弘幸, 久保田洋平, 梅本久美子, 永田祐介, 内田吉保, 小川和起, 砂川優.
8. がん患者および医療従事者を対象とした腫瘍内科領域における遠隔医療に関する意識調査－医療従事者からの回答結果報告－.
谷口浩也, 松永拓真, 田村祐子, 川上武志, 佐竹悠良, 砂川優.
9. 進行頸部食道扁平上皮癌患者に対して Docetaxel/Cisplatin/5-FU と強度変調放射線治療 IMRT を同時併用する根治的化学放射線療法の第Ⅱ相試験.
渡辺晃識, 堅田親利, 川上正悟, 加藤健, 安藤孝将, 對馬隆浩, 野村基雄, 吉井貴子, 伊澤直樹, 小島隆嗣, 朴将源, 細川歩, 山本幸子, 石川秀樹, 浜本康夫.

10. A prospective observational study of MSI screening in chemotherapy-naïve advanced gastric cancer: WJOG13320GPS.
加藤恭子, 小森梓, 廣中秀一, 杉本直俊, 西田謙太郎, 松山仁, 野長瀬祥兼, 坂口智紘, 近藤侑鈴, 中積宏之, 長瀬通隆, 伊澤直樹, 原田一顕, 岩槻政晃, 三梨桂子, 木藤陽介, 川上賢太郎, 陶山浩一, 吉村健一, 室圭.
11. Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes.
澁木太郎, 中村能章, 上野誠, 古川正幸, 川本泰之, 伊藤心二, 梅本久美子, 須藤研太郎, 佐藤太郎, 水野伸匡, 浅木彰則, 岡野尚弘, 清水怜, 大坪公士郎, 松本俊彦, 藤澤孝夫, 坂東英明, 吉野孝之, 森実千種, 池田公史.
12. The utility of circulating tumor DNA in gastrointestinal stromal tumor –a pooled analysis of SCRUM–Japan trials–.
橋本直佳, 中村能章, 小松嘉人, 高橋直樹, 岡野尚弘, 森実千種, 大坪公士郎, 太田高志, 沖英次, 仁科智裕, 安井久晃, 川上尚人, 江崎泰斗, 町田望, 土井綾子, 朴将源, 工藤敏啓, 藤澤孝夫, 坂東英明, 吉野孝之.
13. A phase 2 study of inpatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BITS study).
若林宗弘, 谷口浩也, 結城敏志, 武田弘幸, 三谷誠一郎, 奥村祐太, 赤澤直也, 山口和久, 牧山明資, 工藤敏啓, 工藤千穂, 盛啓太, 室圭.
14. The clinical validity of droplet digital PCR to identify KRAS mutations using blood or cytology specimens in pancreatic cancer.
Kumiko Umemoto, Kazunari Nakahara, Nobuyuki Ohike, Yusuke Satta, Akihiro Sekine, Yosuke Igarashi, Yusuke Nagata, Yohei Kubota, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Naoki Izawa, Hayato Hiraki, Tomoko Norose, Junki Koike, Ryo Matoba, Satoshi Nishizuka, Keisuke Tateishi, Yu Sunakawa.
15. Clinical significance of plasma-based comprehensive genomic profiling in metastatic colorectal cancer by RAS/BRAF status.
小川和起, 新井裕之, 内田吉保, 久保田洋平, 武田弘幸, 永田祐介, 土井綾子, 堀江良樹, 梅本久美子, 伊澤直樹, 中村能章, 吉野孝之, 砂川優.

2024.03 第 96 回日本胃癌学会総会

1. 再発した胃癌・胃食道接合部癌におけるリキッドバイオプシーの CGP 検査: Liquid-GEAR 試験 A liquid biopsy-based CGP testing in recurrent gastric or GEJ cancer: Liquid-GEAR study.
武田 弘幸, 石黒 敦, 川端 良平, 仁科 慎一, 高橋 正純, 鈴木 修平, 鈴木 崇久, 松山 仁, 高橋 政樹, 砂川 優.

2023.06 ASCO

1. Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii.
2. Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.
Takeshi Kuwata, Yoshiaki Nakamura, Tomohiro Nishina, Naoki Takahashi, Hiroto Narimatsu, Hourin Cho, Chiaki Inagaki, Shigenori Kadowaki, Yoshinaga Okugawa, Sawako Matsuzaki, Naohiro Tomita, Hisateru Yasui, Yu Sunakawa, Manami Matsukawa, Kaori Kimura, Yumie Hiraoka, Makoto Hirata, Issei Imoto, Shinji Kosugi, Takayuki Yoshino.
3. Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
Hiroya Taniguchi, Masataka Yagisawa, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Iver Odegaard, Satoshi Fujii, Shogo Nomura, Akihiro Sato, Takayuki Yoshino, Yoshiaki Nakamura.
4. NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino.
5. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Erika P. Hamilton, Hidetoshi Hayashi, Seung Tae Kim, Keun-Wook Lee, Bradley J. Monk, Danny Nguyen, Alicia Frances Clare Okines, David M. O'Malley, Paula R Pohlmann, Martin Reck, Evan Y. Yu, Roman Groisberg, Jorge Ramos, Qianwen Tan, Tom Stinchcombe, Tanios S. Bekaii-Saab.

2023.07 ESMO-GI

1. RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17).
Shinichi Nishina, Naoki Izawa, Megumu Watabe, Toshihiko Matsumoto, Masato Kataoka, Akinori Sugaya, Tomomi Kashiwada, Eiji Oki, Akitaka Makiyama, Yoshihisa Yaguchi, Takashi Ohta, Tatsuya Toyokawa, Yasuyuki Miura, Kazuma Kobayashi, Yosuke Kito, Osamu Muto, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.

2. Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO.
Yu Sunakawa, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Takahisa Kyogoku, Tamotsu Sagawa, Yutaro Kubota, Toshiki Masuishi, Masahito Kotaka, Takashi Sekikawa, Ken Shimada, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, and Akihito Tsuji.

2023.10 ESMO

1. The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer patients with RAS mutation negative in circulating-tumor DNA after 1st or 2nd-line chemotherapy.
Naoki Izawa, Toshihiro Kudo, Satoshi Yuki, Michio Nakamura, Dai Manaka, Yosuke Kumekawa, Takashi Mine, Tatsuya Okuno, Hisanobu Oda, Tamotsu Sagawa, Takashi Kawai, Tatsushi Shingai, Masahito Kotaka, Kenji Kobayashi, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.
2. 555MO – Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13).
Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, M. Matsuura, Y. Shinohara, T. Miyake, T. Sagawa, C. Tanaka, S. Okamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji.
3. 1549P – A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial.
H. Takeda, R. Kawabata, A. Ishiguro, S. Nishina, M. Takahashi, S. Suzuki, T. Suzuki, J. Matsuyama, A. Okita, H. Miyagaki, N. Takegawa, T. Nomura, Y. Kito, H. Yabusaki, Y. Negoro, A. Makiyama, M. Nakamura, M. Takahashi, Y. Sunakawa.
4. 1547P – SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer.
C. Inagaki, R. Matoba, H. Iijima, J. Hihara, H. Yasui, M. Tsuda, T. Suzuki, A. Makiyama, H. Yabusaki, J. Matsuyama, M. Takahashi, Y. Kito, Y. Akamaru, A. Ishiguro, R. Kawabata, Y. Sakamoto, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa.
5. A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G.
Akitaka Makiyama · Hirokazu Shoji · Hisato Kawakami · Takao Tamura · Keiji Sugiyama · Hiroki Hara · Michitaka Nagase · Kazuo Nishikawa · Taito Esaki · Naoki Izawa · Masato Nakamura · Takayuki Ando · Yuji Miura · Yukiya Narita · Mototsugu Shimokawa · Kentaro Yamazaki · Shuichi Hironaka · Ichinosuke Hyodo · Kei Muro.

1. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC).

Koichi Goto, Alison M. Schram, Dong-Wan Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, Michael Duruisseaux, Kumiko Umemoto, Joon Oh Park, Natasha Leighl, Teresa Macarulla, Stephen V. Liu, Mohammed Najeeb Al Hallak, James Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, Shola Adeyemi, Shekeab Jauhari, Alexander E. Drilon.

1. Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX therapy in Japan: A retrospective observational study using administrative database.

Yu Sunakawa, Chaochen Wang, Yongzhe Piao, Long Jin, Yoshinori Tanizawa, Zhihong Cai, Yoshinori Kagawa.

2. A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

Hirofumi Arai, Eisuke Inoue, Masanori Terashima, Eishi Baba, Nobuhisa Matsuhashi, Kei Muro, Toshifumi Yamaguchi, Satoshi Yuki, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.

3. Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts)
- Yu Aoki, Yoshiaki Nakamura, Yoshito Komatsu, Hiroya Taniguchi, Yu Sunakawa, Manabu Shiozawa, Chiyo Kitagawa, Takashi Ohta, Nobuhisa Matsuhashi, Kentaro Yamazaki, Shogen Boku, Naoki Takahashi, Taito Esaki, Hisato Kawakami, Yoshinori Kagawa, Tomohiro Nishina, Kensei Yamaguchi, Hideaki Bando, Takayuki Yoshino.

4. Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR).

Kota Ouchi, Akihito Tsuji, Manabu Shiozawa, Takashi Kawai, Hisateru Yasui, Hirofumi Ota, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Toru Miyake, Tatsuro Yamaguchi, Masato Matsuura, Tamotsu Sagawa, Akitaka Makiyama, Kunihiro Wakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Chikashi Ishioka, Yu Sunakawa.

5. Efficacy of biomarker-matched therapy in clinical trials for advanced gastrointestinal cancers: A pooled analysis of SCRUM-Japan studies.

Tadayoshi Hashimoto, Takao Fujisawa, Nozomu Machida, Akitaka Makiyama, Shogen Boku, Shigenori Kadowaki, Naoki Takahashi, Eiji Oki, Chigusa Morizane, Yu Sunakawa, Yoshito Komatsu, Naohiro Okano, Taito Esaki, Takashi Ohta, Takeshi Kato, Hiroshi Ozaki, Naoko Iida, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino.

6. Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.
Haeseong Park, Tanios S. Bekaii-Saab, Sunnie S. Kim, Michael J. Pishvaian, Yu Sunakawa, Suneel Deepak Kamath, Akihito Kawazoe, Kei Muro, David Bing Zhen, Hidekazu Hirano, Erika Maestas, Patrick Grierson, Naotoshi Sugimoto, Kensei Yamaguchi, Michelle Ubowski, Qianwen Tan, David E. Adelberg, John H Strickler.
7. Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
Taro Shibuki, Yoshiaki Nakamura, Makoto Ueno, Masayuki Furukawa, Yasuyuki Kawamoto, Shinji Itoh, Kumiko Umemoto, Kentaro Sudo, Taroh Satoh, Nobumasa Mizuno, Akinori Asagi, Naohiro Okano, Satoshi Shimizu, Tanios Bekaii-Saab, John H. Strickler, Takao Fujisawa, Hideaki Bando, Takayuki Yoshino, Chigusa Morizane, Masafumi Ikeda.
8. An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study.
Shun Yamamoto, Ken Kato, Hiroshi Saeki, Shigenori Kadowaki, Keiko Minashi, Yuki Kasahara, Motoo Nomura, Tomoyo Yasuda, Yusuke Sato, Kazuo Koyanagi, Naoki Izawa, Morihito Okada, Hironaga Satake, Shuko Morita, Masahiro Goto, Takako Yoshii, Sachiko Yamamoto, Makiko Izawa, Kohei Uemura, Kei Muro.
9. Safety and efficacy of chemotherapy for patients (pts) with unresectable pancreatic cancer (uPC) concomitant with collagen disease: A multicenter retrospective observational study.
Hiroyuki Asama, Hiroyuki Okuyama, Yasuyuki Kawamoto, Kumiko Umemoto, Takuo Yamai, Satoshi Kobayashi, Masafumi Watanabe, Yasuo Hamamoto, Takaaki Furukawa, Yohei Kitano, Masayo Motoya, Yuko Suzuki, Akihiro Ohba, Kazuo Watanabe, Naohiro Okano, Kazuhiko Shioji, Noritoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Makoto Ueno.
10. Comprehensive clinico-molecular profile and efficacy of anti-HER2 therapy for HER2-amplified biliary tract cancer.
Kanae Inoue, Yoshiaki Nakamura, Bennett Caughey, Binbin Zheng-Lin, Makoto Ueno, Masayuki Furukawa, Yasuyuki Kawamoto, Shinji Itoh, Kumiko Umemoto, Kentaro Sudo, Taroh Satoh, Nobumasa Mizuno, Takeshi Kajiwara, Takao Fujisawa, Hideaki Bando, Takayuki Yoshino, John H. Strickler, Tanios Bekaii-Saab, Chigusa Morizane, Masafumi Ikeda.

論文業績(和文)

《原著・総説・解説》

1. 若年膵癌と KRAS 変異.

- 胆と膵, 44(7): 661-663.
- 梅本久美子.

2. FOLFOX+CET/PANI 療法, FOLFIRI+CET/PANI 療法

- ガイドラインに沿った大腸癌薬物療法の要点と盲点, 第 2 版、II 2: 29-35.
- 武田弘幸、砂川優.

3. 消化管がん(食道、胃、大腸)診療におけるゲノム医療の位置づけ

- 腫瘍内科, 31(6):688-694.
- 新井 裕之、砂川 優.

4. 肝細胞がん

- 新臨床腫瘍学 改定第7版, 4(35):447-453.
- 梅本久美子.

5. 消化器がん治療における ctDNA の現状と展望

- 医学のあゆみ, 288 (2) 105-109, 2024..
- 武田 弘幸、砂川 優.

論文業績(英文)

《原著・総説・解説》

1. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
 - Target Oncol. 18(3):359-368, 2023.
 - Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, Yoshio Nagahisa, Kazuhiro Nishikawa, Masazumi Takahashi, Masato Nakamura, Atsushi Ishiguro, Hiroo Katsuya, Jun Hihara, Dai Manaka, Yuji Negoro, Akihito Tsuji, Takao Takahashi, Mitsugu Kochi, Mizutomo Azuma, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa, Masashi Fujii.
2. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
 - Target Oncol. 18(3):369-381, 2023.
 - Naoki Izawa, Toshiki Masuishi, Naoki Takahashi, Hirokazu Shoji, Yoshiyuki Yamamoto, Toshihiko Matsumoto, Keiji Sugiyama, Takeshi Kajiwara, Kentaro Kawakami, Naoki Aomatsu, Chihiro Kondoh, Hisato Kawakami, Naoki Takegawa, Taito Esaki, Mototsugu Shimokawa, Kazuto Nishio, Yukiya Narita, Hiroki Hara, Yu Sunakawa, Narikazu Boku, Toshikazu Moriwaki, Takako Eguchi Nakajima, Kei Muro.
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.
 - ESMO Open. 8(3):101558.
 - Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, Mulansari NA, Govind Babu K, Lee MA, Tan CK, Cornelio G, Chong DQ, Chen LT, Tanasanvimon S, Prasongsook N, Yeh KH, Chua C, Sacdalan MD, Sow Jenson WJ, Kim ST, Chacko RT, Syaiful RA, Zhang SZ, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G.

4. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.

 - Target Oncol. 18(3):369–381.
 - Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwarra T, Kawakami K, Aomatsu N, Kondoh C, Kawakami H, Takegawa N, Esaki T, Shimokawa M, Nishio K, Narita Y, Hara H, Sunakawa Y, Boku N, Moriwaki T, Eguchi Nakajima T, Muro K.
5. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).

 - Target Oncol. 18(3):359–368.
 - Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M.
6. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM–Japan GI-SCREEN: A Nationwide Genomic Profiling Program.

 - JCO Precis Oncol. 7:e2200653.
 - Nakamura Y, Yamashita R, Okamoto W, Komatsu Y, Yuki S, Ueno M, Kato K, Taniguchi H, Kagawa Y, Denda T, Hara H, Esaki T, Moriwaki T, Sunakawa Y, Oki E, Nagashima F, Nishina T, Satoh T, Kawakami H, Yamaguchi K, Ohtsubo K, Kato T, Horita Y, Tsuji A, Yasui H, Goto M, Hamamoto Y, Wakabayashi M, Ikeno T, Shitara K, Bando H, Tsuchihara K, Miki I, Ichiki H, Ohtsu A, Yoshino T.
7. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.

 - Eur J Cancer. 184:10–20.
 - Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M.
8. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

 - Br J Cancer. 128(10):1897–1905.
 - Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwarra T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T.
9. Clinial utility of geriatric assessment tools in older patients with gastrointestinal cancer.

 - Frontiers in oncology. 2023 May 31;13:1110236.
 - Ayako Doi, Takuro Mizukami, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Yoshiaki Horie, Naoki Izawa, Takashi Ogura, Yu Sunakawa.

10. Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.

 - International journal of clinical oncology. 28(9):1166–1175.
 - Mitsuhiro Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita, Naoki Izawa, Saburo Kakizoe, Mototsugu Shimokawa, Tomoharu Yoshizumi, Yoshihiro Kakeji, Masaki Mori, Eiji Oki.
11. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.

 - ESMO OPEN. 27;8(6):102071.
 - Y. Narita, T. Matsushima, Y. Sakamoto, H. Matsuoka, H. Tanioka, T. Kawakami, H. Shoji, T. Mizukami, N. Izawa, T. Nishina, Y. Yamamoto, S. Mitani, M. Nakamura, T. Misumi, K. Muro.
12. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.

 - JCO Precision Oncology. 2023 Jun;7:e2200688.
 - Yu Aoki, Yoshiaki Nakamura, Tadamichi Denda, Takashi Ohta, Taito Esaki, Manabu Shiozawa, Kensei Yamaguchi, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Naohiro Okano, Hiroya Taniguchi, Taro Sato, Eiji Oki, Tomohiro Nishina, Yoshito Komatsu Nobuhisa Matsuhashi, Masahiro Goto, Hisateru Yasui, Koushiro Ohtsubo, Toshikazu Moriwaki, Naoki Takahashi, Yosuke Horita, Shogen Boku, Masashi Wakabayashi, Takashi Ikeno, Ryuta Mitani, Mihoko Yuasa, Takayuki Yoshino.
13. Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.

 - Japanese journal of clinical oncology. 30;53(9):764–773.
 - Hiroshi Imaoka, Masafumi Ikeda, Kumiko Umemoto, Yu Sunakawa, Makoto Ueno, Hideki Ueno, Masato Ozaka, Takamichi Kuwahara, Naohiro Okano, Masashi Kanai, Terumasa Hisano, Yuko Suzuki, Akinori Asagi, Kazuhiko Shioji, Akiko Todaka, Kunihiro Tsuji, Kenji Ikezawa, Ikuya Miki, Yoshito Komatsu, Noriyuki Akutsu, Tatsuya Yamashita, Hiroyuki Okuyama, Junji Furuse, Hiroaki Nagano.
14. Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study.

 - Target Oncol. 18(5):707–715.
 - Seiichi Mitani, Yosuke Kito, Kaori Hino, Kentaro Kawakami, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, Kenji Tsuchihashi, Kyoko Kato, Yoshikane Nonagase, Toshihiko Matsumoto, Mitsuhiro Furuta, Hisato Kawakami.
15. Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials.

 - Cancer Medicine. 2023 Dec 23;13(1):e6818.
 - Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii.

16. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
-
- British Journal of Cancer. 129(6):1032–1039.
 - Eiji Oki, Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, Mototsugu Shimokawa, Daisuke Kotani, Hideaki Bando, Tomohiro Nishina, Takanobu Yamada, Satoshi Yuki, Yukiya Narita, Hiroki Hara, Takashi Ohta, Taito Esaki, Yasuo Hamamoto, Ken Kato, Yoshiyuki Yamamoto, Keiko Minashi, Koushiro Ohtsubo, Naoki Izawa, Hisato Kawakami, Takeshi Kato, Taroh Satoh, Naohiro Okano, Akihito Tsuji, Kentaro Yamazaki, Takayuki Yoshino, and Yoshihiko Maehara.
17. Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
-
- British Journal of Cancer. 2024 Feb;130(2):224–232.
 - Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Hitoshi Arioka, Hirotoshi Iihara, Mitsuhiro Sugawara, Hajime Morita, Ayako Mochizuki, Shuichi Nawata, Keisuke Mishima, Ayako Tsuboya, Tempei Miyaji, Kazunori Honda, Ayako Yokomizo, Naoya Hashimoto, Takeshi Yanagihara, Junki Endo, Takashi Kawaguchi, Naoki Furuya, Yumiko Sone, Yusuke Inada, Yasushi Ohno, Chikatoshi Katada, Naoya Hida, Kana Akiyama, Daisuke Ichikura, Akiko Konomatsu, Takashi Ogura, Takuhiro Yamaguchi, Takako Eguchi Nakajima.
18. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
-
- Ther Adv Med Oncol. 2024 Jan 3;16:17588359231217967.
 - Kubota Y, Shitara K.
19. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
-
- Journal of clinical oncology. 41(36):5569–5578.
 - Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do-Youn Oh, Alicia Okines, David M O’Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas E Stinchcombe, Tanios Bekaii-Saab.
20. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.
-
- ESMO OPEN., Oct;8(5):101636.
 - H Yasui, Y Okita, M Nakamura, T Sagawa, T Watanabe, K Kataoka, D Manaka, K Shiraishi, N Akazawa, T Okuno, T Shimura, M Shiozawa, Y Sunakawa, H Ota, M Kotaka, H Okuyama, M Takeuchi, W Ichikawa, M Fujii, A Tsuji.
21. Microsatellite instability: A 2024 update.
-
- Cancer Science. 2024 Jun;115(6):1738–1748.
 - Hiroyuki Yamamoto, Yoshiyuki Watanabe, Hiroyuki Arai, Kumiko Umemoto, Keisuke Tateishi, Yu Sunakawa.

22. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.

 - Cancer Medicine., Sep;12(18):18702–18716.
 - Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake, Atsuo Takashima, Nobuhisa Matsushashi, Takeshi Kato, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino.
23. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.

 - Gastric Cancer. 2023 Nov;26(6):1063–1068.
 - Yasuhiro Kodaera, Kazuhiro Yoshida, Mitsugu Kochi, Takeshi Sano, Wataru Ichikawa, Yoshihiro Kakeji, Yu Sunakawa, Masahiro Takeuchi, Masashi Fujii.
24. The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer.

 - Future oncology. 2023 Jun;19(17):1165–1174.
 - Chiaki Inagaki, Ryo Matoba, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Eisuke Inoue, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.
25. Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.

 - Japanese journal of clinical oncology. 2023 Aug 30;53(9):764–773.
 - Hiroshi Imaoka, Masafumi Ikeda, Kumiko Umemoto, Yu Sunakawa, Makoto Ueno, Hideki Ueno, Masato Ozaka, Takamichi Kuwahara, Naohiro Okano, Masashi Kanai, Terumasa Hisano, Yuko Suzuki, Akinori Asagi, Kazuhiko Shioji, Akiko Todaka, Kunihiro Tsuji, Kenji Ikezawa, Ikuya Miki, Yoshito Komatsu, Noriyuki Akutsu, Tatsuya Yamashita, Hiroyuki Okuyama, Junji Furuse, Hiroaki Nagano.
26. Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas.

 - Journal of Gastrointest Oncology., 14(5):2083–2096.
 - Bennett A Caughey, Kumiko Umemoto, Michelle F Green, Masafumi Ikeda, Melissa E Lowe, Makoto Ueno, Donna Niedzwiecki, Hiroya Taniguchi, Daniel J Walden, Yoshito Komatsu, Rachel D'Anna, Taito Esaki, Tadamichi Denda, Michael B Datto, Hideaki Bando, Tanios Bekaii-Saab, Takayuki Yoshino, John H Strickler, Yoshiaki Nakamura.
27. The Phase I/II eNRGy Trial: Zenocutuzumab in Patients with Cancers Harboring NRG1 Gene Fusions.

 - Future Oncology. 2024;20(16):1057–1067.
 - Dong-Wan Kim, Alison M. Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, Michaël Duruisseaux, Stephen V. Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M. Cleary, Christoph Springfield, Cindy Neuzillet, Andrew Joe, Shekeab Jauhari, Jim Ford, Koichi Goto.

28. CCCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.

 - J Immunother Cancer.,12(1):e007939.
 - Francesca Battaglin, Yasmine Baca, Joshua Millstein, Yan Yang, Joanne Xiu, Hiroyuki Arai, Jingyuan Wang, Fang-Shu Ou, Federico Innocenti, Shannon M Mumenthaler, Priya Jayachandran, Natsuko Kawanishi, Annika Lenz, Shivani Soni, Sandra Algaze, Wu Zhang, Taline Khoukaz, Evanthia Roussos Torres, Andreas Seeber, Jim P Abraham, Emil Lou, Philip A Philip, Benjamin A Weinberg, Anthony F Shields, Richard M Goldberg, John L Marshall, Alan P Venook, W Michael Korn, Heinz-Josef Lenz.
29. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.

 - Eur J Cancer.,201;113914.
 - Hiroyuki Arai, Yan Yang, Yasmine Baca, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Yohei Kubota, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Sandra Algaze, Shivani Soni, Wu Zhang, Richard M Goldberg, Michael J Hall, Aaron James Scott, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, John Marshall, Sanjay Goel, Joanne Xiu, W Michael Korn, Alan P Venook, Yu Sunakawa, Heinz-Josef Lenz.
30. Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: Results of the Japanese expanded access program.

 - Clinical Colorectal Cancer.,S1533-0028(24)00022-7.
 - Daisuke Kotani, Atsuo Takashima, Takeshi Kato, Taroh Satoh, Toshiki Masuishi, Yoshito Komatsu, Manabu Shiozawa, Taito Esaki, Naoki Izawa, Shinji Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, Toshifumi Yamaguchi, Hiroya Taniguchi, Yasunori Ushida, Toshiya Oizaki, Chiaki Inoue, Takayuki Yoshino.
31. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.

 - Targeted Oncology. 2024 Mar;19(2):181-190.
 - Toshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, Toshiki Masuishi, Yasushi Tsuji, Hirokazu Shoji, Kenro Hirata, Takao Tsuduki, Akitaka Makiyama, Naoki Izawa, Naoki Takahashi, Masahiro Tsuda, Hisateru Yasui, Takashi Ohta, Yosuke Kito, Satoshi Otsu, Shuichi Hironaka, Kentaro Yamazaki, Narikazu Boku, Ichinosuke Hyodo, Kenichi Yoshimura, Kei Muro.
32. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.

 - Journal of clinical oncology. 2023 Dec 20;41(36):5569-5578.
 - Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T.

33. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
-
- Targeted Oncology. 2024 Jan 9;19(1):59–69.
 - Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwarra T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T.
34. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.
-
- Clinical Colorectal Cancer. 2024 Jun 23(2):147–159.e7.
 - Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, Yoshino T.
35. Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials.
-
- Cancer Med. 2023 Dec 23;13(1):e6818.
 - Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii.
36. Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study.
-
- Gastric Cancer. 2023 Jul;26(4):614–625.
 - Daisuke Takahari, Hitoshi Katai, Atsuo Takashima, Naoki Izawa, Naoki Ishizuka, Manabu Ohashi, Shinya Mikami, Takeru Wakatsuki, Izuma Nakayama, Keisho Chin, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Satoru Iwasa, Hirokazu Shoji, Takeyuki Wada, Ayako Doi, Takaki Yoshikawa, Takeshi Sano, Narikazu Boku, Kensei Yamaguchi.